Background

In the early 1960s, molecular biology was confined to research on prokaryotes, including Escherichia coli. At that time, the scientific community was not confident whether the operon hypothesis established by Jacques Monod and François Jacob in bacteria could be directly applied to eukaryotes. The way complex life forms, such as humans and animal cells, read and regulate genetic information was entirely in the realm of the unknown.

The chromatin structure and massive genome size of eukaryotic cells presented clear limitations for existing bacteria-based analytical methods. The field of molecular genetics desperately required new analytical strategies to precisely isolate and identify the molecular machinery responsible for gene transcription within the cell nucleus. Pierre Chambon, a French physician and biochemist, began his research during this period and dedicated his life to uncovering the actual mechanisms of eukaryotic transcriptional control.

Key Discoveries

Pierre Chambron's research team focused on exploring RNA polymerase existing within animal cell nuclei. In 1969, they achieved the isolation and purification of RNA polymerase B (now known as RNA polymerase II), which is responsible for transcribing messenger RNA that encodes proteins, from calf thymus tissue. By demonstrating differences in sensitivity to alpha-amanitin toxin, they identified that, unlike prokaryotes, eukaryotes possess three types of polymerases with differentiated functions.

In 1977, while analyzing the chicken ovalbumin gene, he independently observed a fragmented gene structure where non-coding sequences (introns) were interspersed between coding sequences (exons). In 1981, through collaborative research with Richard Bretagnon, he revealed that the 5' GT and 3' AG nucleotide sequences are highly conserved at both ends of eukaryotic introns. This principle of sequence conservation, known as the Chambon-Brenner rule, became a decisive clue in elucidating the splicing mechanism. Additionally, he demonstrated the existence and sequence characteristics of the TATA box, where the transcription initiation complex forms in eukaryotic promoter regions.

In the mid-1980s, Chambon turned his attention to gene expression regulatory factors. He sequentially cloned the estrogen receptor (ER) and retinoic acid receptor (RAR) genes and decoded their amino acid sequences. He confirmed that lipid-soluble hormones, such as steroids and vitamin A metabolites, pass through the cell membrane, bind to receptor proteins inside the cell nucleus, and directly bind to specific DNA sequences (HRE) to induce target gene expression. This established an integrated model of gene transcriptional control, demonstrating that 48 types of human nuclear receptors share structural similarities and form a single superfamily. In 1994, he founded the IGBMC in Strasbourg, France, and disseminated the Cre-ERT2 inducible gene knockout technology, which allows for the spatiotemporal deletion of genes in mouse models, to researchers worldwide.

Significance and Outlook

Chambon’s research has transformed the paradigm of interpreting disease mechanisms and developing new drugs, extending beyond basic genetics. By elucidating the molecular structure of how nuclear receptors regulate transcription in response to hormones, the biological foundation for the development of tamoxifen and fulvestrant, targeted therapies for breast cancer, was established. The establishment of all-trans retinoic acid (ATRA) combination therapy as a clinical standard in the treatment of acute promyelocytic leukemia is also grounded in the elucidation of the retinoic acid receptor mechanism.

The principles of transcriptional control he established are currently expanding to serve as the theoretical foundation for analyzing epigenetic regulatory complexes and new targeted protein degradation (TPD) technologies. However, because nuclear receptors regulate widespread physiological functions throughout the body, overcoming off-target toxicity and drug resistance remains a challenge. Research to precisely design selective nuclear receptor modulators (SNRMs) that act selectively only in specific tissues or disease cells in vivo is continuing as his legacy.